Article

Risk Factors for Cardiovascular Disease in Children Infected with Human Immunodeficiency Virus-1

Division of Pediatric Clinical Research, Department of Pediatrics, Miller School of Medicine, University of Miami, Miami, FL 33101, USA.
The Journal of pediatrics (Impact Factor: 3.79). 07/2008; 153(4):491-7. DOI: 10.1016/j.jpeds.2008.04.016
Source: PubMed

ABSTRACT

To determine risk factors for cardiovascular disease (CVD) in children infected with human immunodeficiency virus (HIV) compared with nationally representative controls from 2003-2004 National Health and Nutrition Examination Survey (NHANES) data.
A prospective, longitudinal analysis of CVD risk factors in 42 HIV-infected children compared with NHANES controls, with multivariable modeling of demographic, disease-specific, and treatment-related factors contributing to cardiac risk in the HIV cohort.
The 42 children infected with HIV were initially an average of 10.1 years old; 68% were Centers for Disease Control and Prevention pediatric HIV disease stage B or C, and 76% were receiving highly active antiretroviral therapy (HAART). Compared with age- and sex-adjusted NHANES controls, the children infected with HIV had lower weight (-0.46 standard deviation [SD] vs +0.54 SD; P < .001), height (-0.62 SD vs +0.26 SD; P < .001), and body mass index (-0.09 SD vs +0.51 SD; P < .001), a higher level of triglycerides (136 mg/dL vs 90 mg/dL; P < .001), and a lower level of high-density lipoprotein (HDL) cholesterol (47 mg/dL vs 54 mg/dL; P < .001). Protease inhibitor therapy was independently associated with higher triglyceride (P = .02) and low-density lipoprotein cholesterol levels (P = .04) and lower HDL cholesterol level (P = .02); nonnucleoside reverse-transcriptase inhibitor therapy was associated with lower visceral fat (P = .01) and higher HDL cholesterol level (P = .005).
Children infected with HIV have adverse cardiac risk profiles compared with NHANES controls. Antiretroviral therapy has a significant influence on these factors.

Download full-text

Full-text

Available from: Lori J Bechard
  • [Show abstract] [Hide abstract]
    ABSTRACT: Dramatic advances in prevention and treatment of pediatric HIV infection occur in high-resource countries, but only 1% of the 2.3 million HIV-infected children live in these regions. Thus, two pediatric HIV epidemics have evolved, one in high-resource countries and one in low-resource countries. About the first epidemic, effective antiretroviral therapies for HIV in children have prolonged life and quality of life. As in adults, there has been evolution in causes of death over time, with decrease in AIDS-opportunistic infections and increase in 'end-stage AIDS' multiorgan failure, sepsis, and renal disease. In addition, spectrum of disease has changed: drug resistance (primary and acquired), lack of salvage drugs for children, complications of therapy, adherence, mental health, and adolescence-transition to adult care are the main problems that have emerged in the last years. In low-resource countries, few women know they are infected and there is poor access to antiretrovirals to prevent mother-to-child transmission, so children often present to health system with advanced disease and about 1000 infants are newly infected each day. Moreover, both diagnosis of infection in infants and drug access remain problematic: despite rapid progression and high mortality due to HIV in children, few receive treatment and, when available, it is started late. In this current evolving clinical context, we reviewed the epidemiology, clinical features, and treatment-related infectious complications of these two HIV-related epidemics.
    No preview · Article · Mar 2008 · Reviews in Medical Microbiology

  • No preview · Article · Nov 2008 · The Journal of pediatrics
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To date, few studies have looked at cardiovascular disease risk factors and early manifestations of atherosclerosis in HIV-infected children and adolescents." HIV infection has become a chronic dis-ease in pediatric patients, with the poten-tial for long-term survival with exposure to antiretroviral (ARV) therapy. Given the assumptions that the risk of cardiovascular disease (CVD) is related to the duration of combined ARV therapy in adults and that CVD has its origin in youth, one might assume that HIV-infected children treated with ARVs would be at a higher risk of accelerated atherosclerosis. Does CVD begin early in life? Until now, our understanding of the child-hood antecedents of adult CVD was limi-ted, having been based on autopsy stud-ies in teens and young adults who died of accidental causes. The Bogalusa Heart Study measured CVD risk factors in healthy children (HC) and adolescents before death from acci-dental causes [1,2]. The Pathobiological Determinants of Atherosclerosis in the Youth Study analyzed CVD risk factors by post-mortem blood samples obtained at autopsy from 3000 subjects, aged 15–34 years, who died from external causes [3,4]. They demon-strated positive associations between CVD risk factors (e.g., hypertension, tobacco use, obesity and level of low-density lipoprotein cholesterol [LDL-C]), and the presence and extent of arterial lesions. More recently, noninvasive methods have been used to assess anatomical, physiological, mechanical and inflamma-tory changes of atherogenesis in adult and pediatric populations. Early anatomical changes can be exam-ined by measuring the internal and com-mon carotid arterial intima–media thick-ness (CCIMT) by B-mode high-resolution ultrasound. In adults, IMT has been shown to be a reliable and valid noninvasive sur-rogate end point to assess cardiovascular risk, since it is related to cardiovascular risk factors and diseases [5,6]. Physiologic changes can be evaluated by measuring carotid and brachial artery flow-mediated endothelium-dependent dilation (FMD) by ultrasound [7,8]. In adults, endothelial dysfunction measured by FMD has been shown to be an inde-pendent predictor of CVD in both the short and long term [9].
    Full-text · Article · Jun 2009 · Expert Review of Anti-infective Therapy
Show more